Expertise in
17
conditions

Dr. Alan Bryce

Oncology
Alan H. Bryce, MD
14200 W Celebrate Life Way, 
Goodyear, AZ 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
17
conditions
Alan H. Bryce, MD
14200 W Celebrate Life Way, 
Goodyear, AZ 

Overview

Alan Bryce is an Oncologist practicing medicine in Goodyear, Arizona.

Dr. Bryce is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Familial Prostate Cancer, Melanoma, and Urothelial Cancer.

He is actively involved in clinical research, co-authoring 131 peer reviewed articles and participating in 14 clinical trials. Dr. Bryce is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in MN

Hospital Affiliations

City Of Hope Cancer Center Phoenix

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Sanford Health
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 2 Less Insurance Carriers -

Locations

Alan H. Bryce, MD
14200 W Celebrate Life Way, Goodyear, AZ 85338
Other Locations
City of Hope Phoenix Cancer Center
14200 W Celebrate Life Way, Goodyear, AZ 85338
City Of Hope Phoenix Cancer Hospital
14200 W Celebrate Life Way, Goodyear, AZ 85338

Additional Areas of Focus

Dr. Bryce has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase I/IIa Theranostic Study of 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer
A Phase I/IIa Theranostic Study of 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer
Enrollment Status: Recruiting
Publish Date: May 06, 2026
Intervention Type: Drug
Study Drugs: 64Cu-SAR-bisPSMA, 67Cu-SAR-bisPSMA
Study Phase: Phase 1/Phase 2
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Abiraterone Acetate, Prednisone
Study Phase: Phase 2/Phase 3
A Phase II Study of Carboplatin, Cabazitaxel and Abiraterone in High Volume Metastatic Castration Sensitive Prostate Cancer
A Phase II Study of Carboplatin, Cabazitaxel and Abiraterone in High Volume Metastatic Castration Sensitive Prostate Cancer
Enrollment Status: Completed
Publish Date: May 26, 2026
Intervention Type: Drug
Study Drugs: Cabazitaxel, Carboplatin, Abiraterone, Prednisone
Study Phase: Phase 2
RECOVER: Phase 2 Randomized, Double-Blind Trial TREating Hospitalized Patients With COVID-19 With Camostat MesilatE, a TMPRSS2 Inhibitor
RECOVER: Phase 2 Randomized, Double-Blind Trial TREating Hospitalized Patients With COVID-19 With Camostat MesilatE, a TMPRSS2 Inhibitor
Enrollment Status: Completed
Publish Date: November 12, 2024
Intervention Type: Other, Drug
Study Drug: Camostat mesilate
Study Phase: Phase 2
A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts
A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts
Enrollment Status: Unknown
Publish Date: April 05, 2024
Intervention Type: Drug
Study Drug: PT-112
Study Phase: Phase 2
A Phase 1b/2a Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab
A Phase 1b/2a Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab
Enrollment Status: Completed
Publish Date: November 18, 2023
Intervention Type: Biological, Drug
Study Drugs: PT-112, Avelumab
Study Phase: Phase 1/Phase 2
The Circulating Cell-free Genome Atlas Study
The Circulating Cell-free Genome Atlas Study
Enrollment Status: Unknown
Publish Date: September 13, 2023
A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men With Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy
A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men With Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy
Enrollment Status: Completed
Publish Date: April 06, 2021
Intervention Type: Biological
Study Phase: Phase 3
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: October 19, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

131 Total Publications

Rucaparib - drug evaluation: a PARP inhibitor for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer.
Rucaparib - drug evaluation: a PARP inhibitor for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer.
Journal: Future oncology (London, England)
Published: June 18, 2026
Similar Doctors
Expertise in
23
conditions
Expertise in
23
conditions
Referral may be required

AZ - Cancer

5777 E Mayo Blvd, 
Phoenix, AZ 
 (27.4 miles away)
480-933-6836
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Tanios Bekaii-Saab is an Oncologist practicing medicine in Phoenix, Arizona. Dr. Bekaii-Saab is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), Pancreatic Ductal Adenocarcinoma, and Pancreatectomy. Dr. Bekaii-Saab is currently accepting new patients.

Expertise in
20
conditions
Expertise in
20
conditions
Referral may be required

AZ - Cancer

5777 E Mayo Blvd, 
Phoenix, AZ 
 (27.4 miles away)
480-933-6836
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mitesh Borad is an Oncologist practicing medicine in Phoenix, Arizona. Dr. Borad is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Cholangiocarcinoma (Bile Duct Cancer), Pancreatic Cancer, Gallbladder Cancer, Liver Cancer, and Tissue Biopsy.

Expertise in
32
conditions
Dr. Allison C. Rosenthal
Hematology | Oncology
Expertise in
32
conditions
Dr. Allison C. Rosenthal
Hematology | Oncology
Referral may be required

AZ - Cancer

5777 E Mayo Blvd, 
Phoenix, AZ 
 (27.4 miles away)
480-933-6836
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Allison Rosenthal is a Hematologist and an Oncologist practicing medicine in Phoenix, Arizona. Dr. Rosenthal is highly rated in 32 conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Alan Bryce

How do I make an appointment with Dr. Alan Bryce?

You can book an appointment with Dr. Alan Bryce by calling their office at 847-342-6910. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Alan Bryce a top-rated expert for Prostate Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Alan Bryce is classified as an Elite expert for Prostate Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Alan Bryce specialize in?

While Dr. Alan Bryce is a Oncology, they have specific expertise in Prostate Cancer, Familial Prostate Cancer, and Melanoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Alan Bryce participate in research or clinical trials?

Yes. Dr. Alan Bryce has published 131 articles and abstracts on conditions like Prostate Cancer. You can view a list of Dr. Alan Bryce's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Alan Bryce accept my insurance?

Dr. Alan Bryce accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 847-342-6910 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bryce's expertise for a condition
ConditionClose
View All 13 Advanced Conditions
View All 62 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile